CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) announced today that, on January 3,
2017, the compensation committee of the company's board of directors
granted fifteen new non-executive employees options to purchase an
aggregate of 174,500 shares of the company's common stock with a per
share exercise price of $4.33, the closing trading price of the
company's common stock on the NASDAQ Global Market on Tuesday, January
3, 2017. Each option has a ten-year term and will vest over a four-year
term, with one-eighth of the shares subject to the option vesting after
six months and the remaining shares vesting in equal monthly increments.
The stock options were granted pursuant to Rule 5635(c)(4) of the NASDAQ
Listing Rules for equity grants to induce the new employees to enter
into employment with the company.
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See www.cerus.com
for more information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005428/en/
Source: Cerus Corporation